Literature DB >> 24022905

Long-lasting response to crizotinib in brain metastases due to EML4-ALK-rearranged non-small-cell lung cancer.

Yoshiaki Kinoshita1, Yasutaka Koga, Atsuhiko Sakamoto, Kouko Hidaka.   

Abstract

Anaplastic lymphoma kinase (ALK) rearranged non-small-cell lung cancer (NSCLC) is highly responsive to crizotinib, an oral ATP-competitive selective inhibitor of ALK. However, crizotinib exhibits extremely poor blood-brain barrier penetration; therefore, it is considered to play a limited role in the treatment of brain metastases. We present a case of a 50-year-old man with a diagnosis of ALK-rearranged NSCLC with brain metastasis and malignant pleural effusion. Despite the several systemic chemotherapy regimens and whole brain radiotherapy, brain metastasis was refractory; therefore, crizotinib was initiated. A CT scan showed a slight reduction in the brain metastasis and no change in intrathoracic disease 17 weeks after initiating crizotinib. Moreover, CT obtained 12 months after crizotinib treatment revealed brain metastasis without progression. To our knowledge, the present case is the second report of crizotinib-responsive brain metastases due to echinoderm microtubule-associated protein-like 4-ALK (EML4-ALK)-rearranged NSCLC.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24022905      PMCID： PMC3794239          DOI： 10.1136/bcr-2013-200867

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN： 1757-790X


  12 in total

1.  Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib.

Authors:  David M Jackman; Alison J Holmes; Neal Lindeman; Patrick Y Wen; Santosh Kesari; Ana M Borras; Christopher Bailey; Francisca de Jong; Pasi A Jänne; Bruce E Johnson
Journal:  J Clin Oncol       Date:  2006-09-20       Impact factor: 44.544

2.  CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib.

Authors:  Daniel B Costa; Susumu Kobayashi; Shuchi S Pandya; Wee-Lee Yeo; Zhongzhou Shen; Weiwei Tan; Keith D Wilner
Journal:  J Clin Oncol       Date:  2011-03-21       Impact factor: 44.544

3.  Rapid response of brain metastasis to crizotinib in a patient with ALK rearrangement-positive non-small-cell lung cancer.

Authors:  Hiroyasu Kaneda; Isamu Okamoto; Kazuhiko Nakagawa
Journal:  J Thorac Oncol       Date:  2013-04       Impact factor: 15.609

4.  Effects of fractionated radiation on the brain vasculature in a murine model: blood-brain barrier permeability, astrocyte proliferation, and ultrastructural changes.

Authors:  Hong Yuan; M Waleed Gaber; Kelli Boyd; Christy M Wilson; Mohammad F Kiani; Thomas E Merchant
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-11-01       Impact factor: 7.038

5.  Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation.

Authors:  R Porta; J M Sánchez-Torres; L Paz-Ares; B Massutí; N Reguart; C Mayo; P Lianes; C Queralt; V Guillem; P Salinas; S Catot; D Isla; A Pradas; A Gúrpide; J de Castro; E Polo; T Puig; M Tarón; R Colomer; R Rosell
Journal:  Eur Respir J       Date:  2010-07-01       Impact factor: 16.671

6.  Gefitinib as palliative therapy for lung adenocarcinoma metastatic to the brain.

Authors:  Chi Wu; Yun Long Li; Zhao Meng Wang; Zhang Li; Tong Xiao Zhang; Zhong Wei
Journal:  Lung Cancer       Date:  2007-04-16       Impact factor: 5.705

Review 7.  The seed and soil hypothesis: vascularisation and brain metastases.

Authors:  Isaiah J Fidler; Seiji Yano; Ruo-Dan Zhang; Takahashi Fujimaki; Corazon D Bucana
Journal:  Lancet Oncol       Date:  2002-01       Impact factor: 41.316

8.  Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines.

Authors:  Qun Dai; Yi-He Ling; Marie Lia; Yi-Yu Zou; Glenn Kroog; Kenneth K Iwata; Roman Perez-Soler
Journal:  Clin Cancer Res       Date:  2005-02-15       Impact factor: 12.531

9.  Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial.

Authors:  G L Ceresoli; F Cappuzzo; V Gregorc; S Bartolini; L Crinò; E Villa
Journal:  Ann Oncol       Date:  2004-07       Impact factor: 32.976

10.  Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts.

Authors:  Kengo Takeuchi; Young Lim Choi; Manabu Soda; Kentaro Inamura; Yuki Togashi; Satoko Hatano; Munehiro Enomoto; Shuji Takada; Yoshihiro Yamashita; Yukitoshi Satoh; Sakae Okumura; Ken Nakagawa; Yuichi Ishikawa; Hiroyuki Mano
Journal:  Clin Cancer Res       Date:  2008-10-15       Impact factor: 12.531
View more
  13 in total

Review 1.  Current approaches to the treatment of metastatic brain tumours.

Authors:  Taofeek K Owonikoko; Jack Arbiser; Amelia Zelnak; Hui-Kuo G Shu; Hyunsuk Shim; Adam M Robin; Steven N Kalkanis; Timothy G Whitsett; Bodour Salhia; Nhan L Tran; Timothy Ryken; Michael K Moore; Kathleen M Egan; Jeffrey J Olson
Journal:  Nat Rev Clin Oncol       Date:  2014-02-25       Impact factor: 66.675

2.  PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models.

Authors:  Helen Y Zou; Luc Friboulet; David P Kodack; Lars D Engstrom; Qiuhua Li; Melissa West; Ruth W Tang; Hui Wang; Konstantinos Tsaparikos; Jinwei Wang; Sergei Timofeevski; Ryohei Katayama; Dac M Dinh; Hieu Lam; Justine L Lam; Shinji Yamazaki; Wenyue Hu; Bhushankumar Patel; Divya Bezwada; Rosa L Frias; Eugene Lifshits; Sidra Mahmood; Justin F Gainor; Timothy Affolter; Patrick B Lappin; Hovhannes Gukasyan; Nathan Lee; Shibing Deng; Rakesh K Jain; Ted W Johnson; Alice T Shaw; Valeria R Fantin; Tod Smeal
Journal:  Cancer Cell       Date:  2015-07-02       Impact factor: 31.743

Review 3.  ALK inhibitors in non-small cell lung cancer: crizotinib and beyond.

Authors:  Mark M Awad; Alice T Shaw
Journal:  Clin Adv Hematol Oncol       Date:  2014-07

Review 4.  Oral Targeted Therapies and Central Nervous System (CNS) Metastases.

Authors:  Michael P Gabay; Scott M Wirth; Joan M Stachnik; Colleen L Overley; Katie E Long; Linda R Bressler; John L Villano
Journal:  CNS Drugs       Date:  2015-11       Impact factor: 5.749

Review 5.  Treatment Optimization for Brain Metastasis from Anaplastic Lymphoma Kinase Rearrangement Non-Small-Cell Lung Cancer.

Authors:  Wenhui Wang; Xin Sun; Zhouguang Hui
Journal:  Oncol Res Treat       Date:  2019-09-17       Impact factor: 2.825

6.  Real-world outcomes in patients with ALK-positive non-small cell lung cancer treated with crizotinib.

Authors:  K L Davis; J A Kaye; E T Masters; S Iyer
Journal:  Curr Oncol       Date:  2018-02-28       Impact factor: 3.677

7.  A case of orbital metastasis as disease progression of anaplastic lymphoma kinase-positive lung cancer treated with crizotinib.

Authors:  Yoshihiko Sakata; Kodai Kawamura; Kazuya Ichikado; Masakazu Yoshioka
Journal:  Case Rep Oncol       Date:  2015-01-14

Review 8.  Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary?

Authors:  Gouji Toyokawa; Takashi Seto; Mitsuhiro Takenoyama; Yukito Ichinose
Journal:  Cancer Metastasis Rev       Date:  2015-12       Impact factor: 9.264

9.  Activity of crizotinib over choroidal metastases in non-small-cell lung cancer (NSCLC)-ALK rearranged: a case report.

Authors:  Alessandra Bearz; Sandra Santarossa; Antonio Manfrè; Giorgio Beltrame; Martina Urbani; Ivana Sartor; Valentina Da Ros; Umberto Tirelli
Journal:  BMC Res Notes       Date:  2014-09-02

10.  Responses to crizotinib and disease monitoring with circulating tumor cells in lung adenocarcinoma patient with MET exon 14 skipping mutation: A case report.

Authors:  Xiang Tan; Lei Dai; Yongyong Wang; Guanbiao Liang; Nuo Yang; Mingwu Chen
Journal:  Medicine (Baltimore)       Date:  2017-11       Impact factor: 1.817
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.